Newsweek: The New Era of Life Sciences 2024

May 15, 2024 – FACIT President discusses early-stage investing in Canada in an interview with Newsweek’s Investment Reports and appeared in The New Era of Life Sciences 2024. FACIT is an innovative organization focused on bridging the gap between cancer research breakthroughs and their commercialization, thereby accelerating the journey of scientific discoveries from the laboratory to the marketplace.

Read More from Newsweek: The New Era of Life Sciences 2024

FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca

March 20, 2024 – FACIT’s portfolio company Fusion Pharmaceuticals is being acquired by AstraZeneca for a total transaction value of up to $2.4 billion. Congratulations to the team at Fusion for building value over the last decade that will have a lasting impact on patients with cancer and the Ontario economy.

Read More from FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca